جارٍ التحقق…
تُرجمت تلقائيًا. للجرعات والتحذيرات: راجع النص الأصلي بالإنجليزية. اقرأ بالإنجليزية
الرئيسية / Registered in Nigeria / Crinone Vaginal Gel

Crinone Vaginal Gel

NAFDAC Reg. No. C4-1804 · Drug

Registered with NAFDAC. Registration activeAs of 3 November 2026 · synced automatically from official sources.
Product
Crinone Vaginal Gel
رقم NAFDAC
C4-1804
المادة الفعالة
Progesterone
التركيز
8%
الشكل
Gel
حجم العبوة
1 x 15’s (Pre-filled Applicators)
Manufacturer
Not listed
Applicant (holder)
Merck Pharmaceutical and Life Sciences Limited
Approved
3 Aug 2021
الحالة
Inactive View on NAFDAC ↗
التسجيل ساري حتى
2 Aug 2026
تنبيهات منظمة الصحة العالمية
None found
Community reports
None
Times checked
0

About the medicine: Progesterone: uses, dosage and brands worldwide

What we found

  • Crinone Vaginal Gel is on the NAFDAC register with an active registration (C4-1804). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Crinone Vaginal Gel

ما تقوله النشرة الرسمية. إذا وصفه لك طبيب، فاتبع الوصفة. وإذا اختلفت نشرة عبوتك، فالأولوية لها.

تحذير خطير: CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY Cardiovascular Disorders and Probable Dementia Estrogens plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS , Cardiovascular disorders and Probable dementia . …
لمن هو

Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea.

كيف يُتناول وكم مرة
  • Prevention of Endometrial Hyperplasia Progesterone capsules should be given as a single daily dose at bedtime, 200 mg orally for 12 days sequentially per 28-day cycle, to postmenopausal women with a uterus who are receiving daily conjugated estrogens tablets
  • Treatment of Secondary Amenorrhea Progesterone capsules may be given as a single daily dose of 400 mg at bedtime for 10 days
  • Some women may experience difficulty swallowing progesterone capsules
  • For these women, progesterone capsules should be taken with a glass of water while in the standing position
Children
  • Pediatric Use Progesterone capsules are not indicated in children
  • Clinical studies have not been conducted in the pediatric population
Older adults

H. Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing progesterone capsules to determine whether those over 65 years of age differ from younger subjects in their response to progesterone capsules. …

While you are taking it
  • Patient Information General: This product contains peanut oil and should not be used if you are allergic to peanuts
  • Physicians are advised to discuss the contents of the Patient Information leaflet with patients for whom they prescribe PROGESTERONE Capsules
  • PATIENT INFORMATION Progesterone Capsules, 100 mg Progesterone Capsules, 200 mg Read this PATIENT INFORMATION before you start taking progesterone capsules and read what you get each time you refill your progesterone capsules prescription
  • There may be new information
  • This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. …
Talk to a doctor first if
  • Progesterone capsules should not be used in women with any of the following conditions: Progesterone capsules should not be used in patients with known hypersensitivity to its ingredients
  • Progesterone capsules contain peanut oil and should never be used by patients allergic to peanuts
  • Undiagnosed abnormal genital bleeding
  • Known, suspected, or history of breast cancer
  • Active deep vein thrombosis, pulmonary embolism or history of these conditions. …
Warnings

See BOXED WARNING . 1. Cardiovascular disorders An increased risk of pulmonary embolism, deep vein thrombosis (DVT), stroke, and myocardial infarction has been reported with estrogen plus progestin therapy. Should any of these occur or be suspected, estrogen with progestin therapy should be discontinued immediately. Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (for example, personal history or family history of venous thromboembolism [VTE], obesity, and systemic lupus erythematosus) should be managed appropriately. a. …

الآثار الجانبية المحتملة

See BOXED WARNING , WARNINGS and PRECAUTIONS. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In a multicenter, randomized, double-blind, placebo-controlled clinical trial, the effects of progesterone capsules on the endometrium was studied in a total of 875 postmenopausal women. …

Pregnancy and breastfeeding

E. Pregnancy Progesterone capsules should not be used during pregnancy. (See CONTRAINDICATIONS .) Pregnancy Category B: Reproductive studies have been performed in mice at doses up to 9 times the human oral dose, in rats at doses up to 44 times the human oral dose, in rabbits at a dose of 10 mcg/day delivered locally within the uterus by an implanted device, in guinea pigs at doses of approximately one-half the human oral dose and in rhesus monke …

If you take too much

No studies on overdosage have been conducted in humans. In the case of overdosage, progesterone capsules should be discontinued and the patient should be treated symptomatically.

إذا نسيت جرعة

تناولها عندما تتذكر، إلا إذا اقترب موعد الجرعة التالية. عندها تخطَّ الجرعة المنسية. لا تتناول جرعتين معًا أبدًا للتعويض. راجع النشرة، فبعض الأدوية مختلفة.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2025-05-16.

Label for progesterone, the active ingredient registered with NAFDAC.

Check your pack of Crinone Vaginal Gel

Add the expiry date on your pack for a full Trust Score.

أو التقط صورًا للعبوة
تبقّت 3 عمليات تحقق مجانية اليوم Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Crinone Vaginal Gel

What is in Crinone Vaginal Gel?

Crinone Vaginal Gel contains Progesterone (8%), as gel, according to its NAFDAC registration record.

Is Crinone Vaginal Gel registered with NAFDAC?

Yes. Crinone Vaginal Gel is listed on the NAFDAC register under registration number C4-1804, and its registration is active as of 3 November 2026.

Has Crinone Vaginal Gel been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Crinone Vaginal Gel in our automatically synced alert list.

How can I check that my pack of Crinone Vaginal Gel is genuine?

Run a free authenticity scan with the NAFDAC number C4-1804, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Crinone Vaginal Gel?

Follow your prescription or the leaflet in your pack. The official label says: Prevention of Endometrial Hyperplasia Progesterone capsules should be given as a single daily dose at bedtime, 200 mg orally for 12 days sequentially per 28-day cycle, to postmenopausal women with a uterus who are receiving daily conjugated estrogens tablets. Treatment of Secondary Amenorrhea Progesterone capsules may be given as a single daily dose of 400 mg at bedtime for 10 …

What is Crinone Vaginal Gel used for?

Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea. (Summarised from the official U.S. FDA label for progesterone. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Crinone Vaginal Gel? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.